MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (MAIA)
Company Research
Source: Business Wire
Expansion of 2021 clinical supply agreement for Phase 2 clinical trialNext stage of trial to further assess efficacy of THIO in third line non-small cell lung cancer patientsMAIA expects new patient enrollment to begin soon in the expansion of THIO-101 CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has amended the 2021 clinical supply agreement with Regeneron for the expansion portion of THIO-101, its Phase 2 clinical trial evaluating THIO in sequential administration with cemiplimab (Libtayo®). The new expansion will further assess the efficacy of MAIA’s lead asset, THIO, sequenced with immune checkpoint inhibitor (CPI) Libtayo® (cemiplimab) for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy who were resistant to previous checkpoint inhibitor treatments and chemotherapy.The original
Show less
Read more
Impact Snapshot
Event Time:
MAIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAIA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAIA alerts
High impacting MAIA Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
MAIA
News
- MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings [Yahoo! Finance]Yahoo! Finance
- MAIA Biotechnology Announces Director Participation in Recent Private Placement ClosingsBusiness Wire
- MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas [Yahoo! Finance]Yahoo! Finance
- MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade GliomasBusiness Wire
- MAIA Biotechnology Announces Private Placement of Approximately $950,000Business Wire
MAIA
Earnings
- 11/12/24 - Beat
MAIA
Sec Filings
- 12/20/24 - Form 8-K
- 12/13/24 - Form 4
- 12/13/24 - Form 4
- MAIA's page on the SEC website